Brucellosis Vaccines

Global Brucellosis Vaccines Market to Reach US$306.0 Million by 2030

The global market for Brucellosis Vaccines estimated at US$249.3 Million in the year 2024, is expected to reach US$306.0 Million by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. RB51 Vaccine, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$162.0 Million by the end of the analysis period. Growth in the S19 Vaccine segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.9 Million While China is Forecast to Grow at 6.6% CAGR

The Brucellosis Vaccines market in the U.S. is estimated at US$67.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$61.3 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Brucellosis Vaccines Market – Key Trends & Drivers Summarized

What Are Brucellosis Vaccines and Why Are They Critical in Veterinary and Human Health?

Brucellosis vaccines are crucial in preventing Brucella infections, which affect livestock and, in some cases, humans. Brucellosis, caused by Brucella bacteria, is a highly contagious zoonotic disease that leads to reproductive failures in animals and severe health complications in humans, including fever, joint pain, and fatigue. The disease is most prevalent in cattle, sheep, goats, and pigs, with transmission occurring through direct contact, contaminated feed, or unpasteurized dairy products. Vaccination remains the most effective preventive measure, reducing economic losses in the livestock industry and minimizing the risk of human infection. The most commonly used vaccines include S19, RB51 (for cattle), and Rev-1 (for sheep and goats), all of which help in controlling the spread of brucellosis at a large scale. Recent advancements in recombinant vaccines, DNA vaccines, and vector-based vaccines have further enhanced immunogenicity, safety, and longevity of protection.

How Are Emerging Technologies Transforming the Brucellosis Vaccine Landscape?

With advancements in biotechnology and immunology, brucellosis vaccine development has evolved significantly. Traditional live-attenuated vaccines like S19 and RB51, though effective, carry risks of residual virulence and are restricted in certain cases due to biosafety concerns. Modern vaccine strategies now focus on genetically modified vaccines that retain immunogenicity while reducing risks of pathogenicity. Research is also driving innovation in subunit vaccines, which use specific bacterial antigens to trigger immunity without introducing live bacteria. Furthermore, nano-adjuvants and liposomal delivery systems are enhancing vaccine efficacy and stability, improving immune response in livestock. The rise of One Health initiatives—which integrate human, animal, and environmental health strategies—has led to increased surveillance and adoption of vaccines in endemic regions. Governments and organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) are working to implement mass vaccination programs, serological monitoring, and improved veterinary infrastructure to eradicate the disease globally.

The Growth in the Brucellosis Vaccines Market Is Driven by Several Factors…

Key growth drivers include rising livestock population, increasing awareness about zoonotic diseases, and stringent government regulations on disease control. Growing investments in veterinary biologics and R&D for novel vaccine formulations have further fueled market expansion. The global demand for safe livestock products and dairy safety regulations has led to an uptick in vaccine adoption. Additionally, climate change and global trade expansion are influencing the spread of brucellosis, prompting nations to implement preventive vaccination strategies. The expansion of veterinary clinics, diagnostic laboratories, and livestock management programs is also bolstering the market. In regions such as Asia-Pacific and Africa, where brucellosis remains endemic, government-backed vaccination initiatives are accelerating the demand for advanced vaccines, making the industry poised for significant growth.

SCOPE OF STUDY:

The report analyzes the Brucellosis Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine, Other Types); Application (Cattle Application, Sheep Application, Goat Application)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Anicon Labor GmbH
• Biogenesis Bago
• Bioveta a.s.
• Boehringer Ingelheim
• Ceva Santé Animale
• Colorado Serum Company
• CZ Vaccines
• Fivet Animal Health
• Hester Biosciences Limited
• Indian Immunologicals Ltd.
• Jordan Bio-Industries Center (JOVAC)
• Laboratorios Tornel
• Merck & Co., Inc.
• MSD Animal Health
• Phibro Animal Health Corporation
• Vaxxinova
• VETAL Animal Health Products Inc.
• Veterinary Technologies Corporation
• Virbac
• Zoetis Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.